S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Log in
NASDAQ:SIEN

Sientra Competitors

$4.72
+0.09 (+1.95 %)
(As of 01/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.50
Now: $4.72
$4.79
50-Day Range
$3.85
MA: $4.35
$5.55
52-Week Range
$1.00
Now: $4.72
$7.27
Volume589,506 shs
Average Volume537,429 shs
Market Capitalization$237.89 million
P/E RatioN/A
Dividend YieldN/A
Beta1.81

Competitors

Sientra (NASDAQ:SIEN) Vs. IVC, SMTI, LAKE, HSGX, SRGA, and SRGA

Should you be buying SIEN stock or one of its competitors? Companies in the industry of "surgical appliances & supplies" are considered alternatives and competitors to Sientra, including Invacare (IVC), Sanara MedTech (SMTI), Lakeland Industries (LAKE), Histogenics (HSGX), Surgalign (SRGA), and Surgalign (SRGA).

Invacare (NYSE:IVC) and Sientra (NASDAQ:SIEN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Invacare and Sientra, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Invacare00203.00
Sientra00603.00

Invacare currently has a consensus price target of $14.00, indicating a potential upside of 40.99%. Sientra has a consensus price target of $7.20, indicating a potential upside of 52.70%. Given Sientra's higher probable upside, analysts clearly believe Sientra is more favorable than Invacare.

Volatility & Risk

Invacare has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Comparatively, Sientra has a beta of 1.81, meaning that its stock price is 81% more volatile than the S&P 500.

Valuation & Earnings

This table compares Invacare and Sientra's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Invacare$927.96 million0.37$-53,330,000.00($1.06)-9.37
Sientra$83.70 million2.84$-106,820,000.00($2.29)-2.06

Invacare has higher revenue and earnings than Sientra. Invacare is trading at a lower price-to-earnings ratio than Sientra, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Invacare and Sientra's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Invacare-4.87%-8.76%-3.07%
Sientra-123.88%-174.05%-38.97%

Institutional and Insider Ownership

96.7% of Invacare shares are owned by institutional investors. Comparatively, 71.0% of Sientra shares are owned by institutional investors. 3.2% of Invacare shares are owned by insiders. Comparatively, 2.8% of Sientra shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Invacare beats Sientra on 8 of the 13 factors compared between the two stocks.

Sanara MedTech (NASDAQ:SMTI) and Sientra (NASDAQ:SIEN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, risk and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Sanara MedTech and Sientra, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sanara MedTech0000N/A
Sientra00603.00

Sientra has a consensus target price of $7.20, indicating a potential upside of 52.70%. Given Sientra's higher possible upside, analysts plainly believe Sientra is more favorable than Sanara MedTech.

Volatility & Risk

Sanara MedTech has a beta of 2.43, indicating that its share price is 143% more volatile than the S&P 500. Comparatively, Sientra has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500.

Valuation & Earnings

This table compares Sanara MedTech and Sientra's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sanara MedTech$11.77 million22.76$-2,810,000.00N/AN/A
Sientra$83.70 million2.84$-106,820,000.00($2.29)-2.06

Sanara MedTech has higher earnings, but lower revenue than Sientra.

Profitability

This table compares Sanara MedTech and Sientra's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sanara MedTech-39.58%-175.36%-55.40%
Sientra-123.88%-174.05%-38.97%

Institutional & Insider Ownership

71.0% of Sientra shares are owned by institutional investors. 78.4% of Sanara MedTech shares are owned by company insiders. Comparatively, 2.8% of Sientra shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Sientra beats Sanara MedTech on 7 of the 12 factors compared between the two stocks.

Lakeland Industries (NASDAQ:LAKE) and Sientra (NASDAQ:SIEN) are both small-cap industrial products companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, risk and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Lakeland Industries and Sientra, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Lakeland Industries00303.00
Sientra00603.00

Lakeland Industries currently has a consensus target price of $31.3333, indicating a potential upside of 15.32%. Sientra has a consensus target price of $7.20, indicating a potential upside of 52.70%. Given Sientra's higher possible upside, analysts plainly believe Sientra is more favorable than Lakeland Industries.

Volatility & Risk

Lakeland Industries has a beta of 0.03, indicating that its share price is 97% less volatile than the S&P 500. Comparatively, Sientra has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500.

Valuation & Earnings

This table compares Lakeland Industries and Sientra's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lakeland Industries$107.81 million2.02$3.28 million$0.4560.38
Sientra$83.70 million2.84$-106,820,000.00($2.29)-2.06

Lakeland Industries has higher revenue and earnings than Sientra. Sientra is trading at a lower price-to-earnings ratio than Lakeland Industries, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Lakeland Industries and Sientra's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Lakeland Industries18.93%28.75%24.67%
Sientra-123.88%-174.05%-38.97%

Institutional & Insider Ownership

70.8% of Lakeland Industries shares are owned by institutional investors. Comparatively, 71.0% of Sientra shares are owned by institutional investors. 4.9% of Lakeland Industries shares are owned by company insiders. Comparatively, 2.8% of Sientra shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Lakeland Industries beats Sientra on 8 of the 13 factors compared between the two stocks.

Histogenics (NASDAQ:HSGX) and Sientra (NASDAQ:SIEN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, risk and institutional ownership.

Institutional & Insider Ownership

40.4% of Histogenics shares are owned by institutional investors. Comparatively, 71.0% of Sientra shares are owned by institutional investors. 19.7% of Histogenics shares are owned by company insiders. Comparatively, 2.8% of Sientra shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Volatility & Risk

Histogenics has a beta of 3.1, indicating that its share price is 210% more volatile than the S&P 500. Comparatively, Sientra has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500.

Profitability

This table compares Histogenics and Sientra's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
HistogenicsN/A-34.96%18.40%
Sientra-123.88%-174.05%-38.97%

Valuation & Earnings

This table compares Histogenics and Sientra's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HistogenicsN/AN/A$-8,640,000.00($0.79)-2.76
Sientra$83.70 million2.84$-106,820,000.00($2.29)-2.06

Histogenics has higher earnings, but lower revenue than Sientra. Histogenics is trading at a lower price-to-earnings ratio than Sientra, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Histogenics and Sientra, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Histogenics0000N/A
Sientra00603.00

Sientra has a consensus target price of $7.20, indicating a potential upside of 52.70%. Given Sientra's higher possible upside, analysts plainly believe Sientra is more favorable than Histogenics.

Summary

Histogenics beats Sientra on 7 of the 12 factors compared between the two stocks.

Surgalign (NASDAQ:SRGA) and Sientra (NASDAQ:SIEN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, profitability, institutional ownership and dividends.

Insider and Institutional Ownership

53.5% of Surgalign shares are held by institutional investors. Comparatively, 71.0% of Sientra shares are held by institutional investors. 3.7% of Surgalign shares are held by insiders. Comparatively, 2.8% of Sientra shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

Surgalign has a beta of 2.21, suggesting that its stock price is 121% more volatile than the S&P 500. Comparatively, Sientra has a beta of 1.81, suggesting that its stock price is 81% more volatile than the S&P 500.

Profitability

This table compares Surgalign and Sientra's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Surgalign-56.07%-101.34%-18.44%
Sientra-123.88%-174.05%-38.97%

Earnings & Valuation

This table compares Surgalign and Sientra's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Surgalign$308.38 million0.55$-211,640,000.00($0.16)-13.00
Sientra$83.70 million2.84$-106,820,000.00($2.29)-2.06

Sientra has lower revenue, but higher earnings than Surgalign. Surgalign is trading at a lower price-to-earnings ratio than Sientra, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for Surgalign and Sientra, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Surgalign00203.00
Sientra00603.00

Surgalign presently has a consensus price target of $5.00, indicating a potential upside of 140.38%. Sientra has a consensus price target of $7.20, indicating a potential upside of 52.70%. Given Surgalign's higher possible upside, equities research analysts clearly believe Surgalign is more favorable than Sientra.

Summary

Surgalign beats Sientra on 9 of the 13 factors compared between the two stocks.

Surgalign (NASDAQ:SRGA) and Sientra (NASDAQ:SIEN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, profitability, institutional ownership and dividends.

Insider and Institutional Ownership

53.5% of Surgalign shares are held by institutional investors. Comparatively, 71.0% of Sientra shares are held by institutional investors. 3.7% of Surgalign shares are held by insiders. Comparatively, 2.8% of Sientra shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

Surgalign has a beta of 2.21, suggesting that its stock price is 121% more volatile than the S&P 500. Comparatively, Sientra has a beta of 1.81, suggesting that its stock price is 81% more volatile than the S&P 500.

Profitability

This table compares Surgalign and Sientra's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Surgalign-56.07%-101.34%-18.44%
Sientra-123.88%-174.05%-38.97%

Earnings & Valuation

This table compares Surgalign and Sientra's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Surgalign$308.38 million0.55$-211,640,000.00($0.16)-13.00
Sientra$83.70 million2.84$-106,820,000.00($2.29)-2.06

Sientra has lower revenue, but higher earnings than Surgalign. Surgalign is trading at a lower price-to-earnings ratio than Sientra, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for Surgalign and Sientra, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Surgalign00203.00
Sientra00603.00

Surgalign presently has a consensus price target of $5.00, indicating a potential upside of 140.38%. Sientra has a consensus price target of $7.20, indicating a potential upside of 52.70%. Given Surgalign's higher possible upside, equities research analysts clearly believe Surgalign is more favorable than Sientra.

Summary

Surgalign beats Sientra on 9 of the 13 factors compared between the two stocks.


Sientra Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Invacare logo
IVC
Invacare
1.6$9.93+1.3%$341.77 million$927.96 million-8.07Gap Up
SMTI
Sanara MedTech
0.8$42.56+1.3%$267.87 million$11.77 million-32.99
Lakeland Industries logo
LAKE
Lakeland Industries
1.6$27.17+0.3%$217.90 million$107.81 million7.72Insider Selling
Gap Down
Histogenics logo
HSGX
Histogenics
0.7$2.18+3.2%$206.23 millionN/A-2.76
SRGA
Surgalign
1.3$2.08+1.0%$169.30 million$308.38 million-1.16
SRGA
Surgalign
1.4$2.08+1.0%$169.30 million$308.38 million-1.16
Conformis logo
CFMS
Conformis
1.3$1.40+0.7%$120.32 million$77.43 million-4.12News Coverage
CLGN
CollPlant Biotechnologies
0.7$14.59+0.8%$82.73 million$2.32 million-7.30Gap Up
ReWalk Robotics logo
RWLK
ReWalk Robotics
1.0$2.63+0.4%$65.11 million$4.87 million-2.09Gap Up
POAI
Predictive Oncology
0.6$1.36+0.7%$27.80 million$1.41 million-0.22News Coverage
Gap Up
AHPI
Allied Healthcare Products
0.5$6.65+3.3%$26.67 million$31.89 million0.00News Coverage
NAOV
NanoVibronix
0.5$1.38+1.4%$14.58 million$530,000.00-2.30High Trading Volume
News Coverage
Gap Down
This page was last updated on 1/24/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.